These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 7466730)

  • 41. Cholesterol, colestipol and coronary heart disease.
    Stone NJ
    J Chronic Dis; 1978 Jan; 31(1):1-3. PubMed ID: 346595
    [No Abstract]   [Full Text] [Related]  

  • 42. Colestipol tablets in adolescents with familial hypercholesterolaemia.
    Tonstad S; Ose L
    Acta Paediatr; 1996 Sep; 85(9):1080-2. PubMed ID: 8888922
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Acute digoxin overdosage: potential role of colestipol therapy.
    Hamburger S; Covinsky JO; Styczynski M; Uhrig L
    J Kans Med Soc; 1980 Oct; 81(10):464. PubMed ID: 7229494
    [No Abstract]   [Full Text] [Related]  

  • 44. [Probucol : comparison of its effect with that of a placebo in hyperlipoproteinemia type II].
    Beaumont V
    Nouv Presse Med; 1980 Oct; 9(40):3011-3. PubMed ID: 7443442
    [No Abstract]   [Full Text] [Related]  

  • 45. Colestipol plus fenofibrate versus synvinolin in familial hypercholesterolaemia.
    Weisweiler P; Schwandt P
    Lancet; 1986 Nov; 2(8517):1212-3. PubMed ID: 2877340
    [No Abstract]   [Full Text] [Related]  

  • 46. [Effect of combined treatment with lovastatin and colestipol on serum lipids and lipoproteins].
    Kłosiewicz-Latoszek L; Nowicka G; Szostak WB
    Wiad Lek; 1993 Aug; 46(15-16):581-5. PubMed ID: 7975581
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Plasma 25-hydroxy-vitamin D in familial hypercholesterolemic children receiving colestipol resin.
    Tsang RC; Roginsky MS; Mellies MJ; Glueck CJ
    Pediatr Res; 1978 Oct; 12(10):980-2. PubMed ID: 724301
    [No Abstract]   [Full Text] [Related]  

  • 48. [Effect of probucol on serum cholesterol concentration in primary hyperlipoproteinemia].
    Kawecka-Jaszcz K; Kocemba J; Wasowicz B; Król W
    Kardiol Pol; 1982; 25(5-6):377-82. PubMed ID: 6759746
    [No Abstract]   [Full Text] [Related]  

  • 49. Effect of lipid-lowering therapy on the progression of coronary atherosclerosis assessed by scheduled repetitive coronary arteriography.
    Nash DT; Gensini G; Esente P
    Int J Cardiol; 1982; 2(1):43-55. PubMed ID: 7129689
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Clinical effectiveness of acipimox and fenofibrate in patients with hyperlipoproteinemia type II].
    Chojnowska-Jezierska J; Jabłoński S; Tkaczewski W
    Wiad Lek; 1993 May; 46(9-10):332-6. PubMed ID: 8236987
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The effect of I.V. glucagon administration on selected metabolic parameters in patients with type IIa, IIb and IV primary hyperlipoproteinaemia.
    Andĕl M; Brodan V; Kucerová L; Brodanová M
    Acta Univ Carol Med (Praha); 1980; 26(5-6):271-92. PubMed ID: 7347126
    [No Abstract]   [Full Text] [Related]  

  • 52. Colestipol-niacin therapy and coronary atherosclerosis.
    JAMA; 1987 Nov; 258(19):2694-6. PubMed ID: 3669238
    [No Abstract]   [Full Text] [Related]  

  • 53. [Long-term therapy of familial hypercholesterolemia in young patients with colestipol: availability of minerals and vitamins].
    Schlierf G; Vogel G; Kohlmeier M; Vuilleumier JP; Hüppe R; Schmidt-Gayk H
    Klin Wochenschr; 1985 Sep; 63(17):802-6. PubMed ID: 3932748
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Low dose colestipol in adolescents with familial hypercholesterolaemia.
    Tonstad S; Sivertsen M; Aksnes L; Ose L
    Arch Dis Child; 1996 Feb; 74(2):157-60. PubMed ID: 8660081
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Growth hormone induces low-density lipoprotein clearance but not bile acid synthesis in humans.
    Lind S; Rudling M; Ericsson S; Olivecrona H; Eriksson M; Borgström B; Eggertsen G; Berglund L; Angelin B
    Arterioscler Thromb Vasc Biol; 2004 Feb; 24(2):349-56. PubMed ID: 14656733
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The RED-LIP study--pravastatin in primary isolated hypercholesterolemia--an open, prospective, multicenter trial.
    Sinzinger H; Pirich C
    Wien Klin Wochenschr; 1994; 106(23):721-7. PubMed ID: 7856175
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Bile acid sequestrants and cholesterol.
    Schon P
    N Z Med J; 1990 Apr; 103(887):163. PubMed ID: 2111529
    [No Abstract]   [Full Text] [Related]  

  • 58. [Estimation of the correlation between hemostatic parameters and serum lipids in patients with hyperlipidemia type II after simvastatin therapy].
    Broncel M; Marczyk I; Kostka B; Michalska M; Sikora J; Chojnowska-Jezierska J
    Pol Merkur Lekarski; 2007 Jan; 22(127):21-4. PubMed ID: 17477084
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Induracin, prolonged-action nicotinic acid, in the treatment of atherogenic dyslipoproteinemia].
    Kiseleva NG
    Klin Med (Mosk); 1994; 72(3):20-4. PubMed ID: 7990345
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Type III hyperlipoproteinaemia: the turnover rate of plasma triglycerides and the response to clofibrate.
    Stuyt PM; Demacker PN; Stalenhoef AF; Schade RW; Lutterman JA; van't Laar A
    Neth J Med; 1982; 25(8):245-54. PubMed ID: 7144991
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.